NICE recommends Tremfya

NICE has approved Tremfya (guselkumab) for the treatment of adults with moderate to severe plaque psoriasis. NICE says guselkumab, which is the first biologic to selectively target interleukin (IL)-23, can be used if:

• The disease is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 101

• The disease has not responded to other systemic therapies, including PUVA, ciclosporin and methotrexate, or these options are contra-indicated or not tolerated.


Clinical review: Antihypertensive medication

Paracetamol, pregnancy and language